Clinical trials: Interstitial Fibrosis
Idiopathic Pulmonary Fibrosis (IPF)
Downhill Walking in IPF
In this study; will examine the effects of downhill walking (eccentric exercise training) on exercise capacity, quality of life, and blood lactate levels in individuals with IPF.
- Trial name
- NCT06756230
- Testing
- Pulmonary Rehabilitation, Downhill Walking, Treadmill Walking without incline
- Where
- Turkey (Türkiye)
- Volunteers
- 34 people
- Sponsor
- Saglik Bilimleri Universitesi
Idiopathic Pulmonary Fibrosis (IPF), Sarcoidosis Lung
A Comparison of a Medication Adherence Platform (FORTISKAP™) vs. Usual Care in Subjects on Oral Medications for the Treatment of Interstitial Lung Disease, Sarcoid and Pulmonary Hypertension
This study will evaluate whether participants with serious lung diseases such as idiopathic pulmonary fibrosis, sarcoidosis, and pulmonary hypertension who use the FORTISKAP™ smart medication cap - a bottle-top device that tracks…
- Conditions
- Idiopathic Pulmonary Fibrosis (IPF), Sarcoidosis Lung, Pulmonary Hypertension, Usual Interstitial Pneumonia
- Trial name
- NCT07613216
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Cosmos Rx, Inc
Idiopathic Pulmonary Fibrosis (IPF)
Treatment of Idiopathic Pulmonary Fibrosis With Thalidomide
The goal of this study is to determine whether thalidomide can stop the progression of fibrosis in IPF. The primary objective of this study is to determine the safety, feasibility and efficacy of 400 mg of thalidomide…
- Trial name
- NCT00162760
- Testing
- Thalidomide
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Johns Hopkins University
Pulmonary Fibrosis
A Trial of HRS-9813 Capsule and Tablet in Healthy Subjects
This is a phase Ⅰ study to evaluate the relative bioavailability of HRS-9813 capsule and tablet in healthy subjects and the effect of food on the pharmacokinetics of HRS-9813 capsule.
- Trial name
- NCT06939504
- Testing
- HRS-9813 Capsule, HRS-9813 Tablet
- Where
- China
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Guangdong Hengrui Pharmaceutical Co., Ltd
Idiopathic Pulmonary Fibrosis
Impulse Oscillometry for Prognostication in Idiopathic Pulmonary Fibrosis
A 5-point decline of forced vital capacity expressed as % predicted, over 6 months, is the current definition of disease progression (fast decline in lung function) in idiopathic pulmonary fibrosis.
- Trial name
- OSCILLO (NCT03898284)
- Testing
- Impulse Oscillometry
- Where
- 4 sites in France
- Volunteers
- 54 people
- Sponsor
- University Hospital, Tours
Idiopathic Pulmonary Fibrosis
A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Idiopathic Pulmonary Fibrosis
The purpose of this study is to evaluate the efficacy, safety, and tolerability of BMS-986278 in participants with Idiopathic Pulmonary Fibrosis.
- Trial name
- NCT06003426
- Testing
- BMS-986278
- Where
- 390 sites in United States, Argentina and 31 more
- Volunteers
- 1,255 people
- Sponsor
- Bristol-Myers Squibb
Idiopathic Pulmonary Fibrosis
Trial Of IW001 in Patients With Idiopathic Pulmonary Fibrosis
This is an open label, Phase One, multicenter study, designed to evaluate the safety, tolerability, to explore the biologic effects, and to explore the clinical effects of the following doses of IW001: 0.1mg/day, 0.5 mg/day, and…
- Trial name
- NCT01199887
- Testing
- IW001
- Where
- 11 sites in United States
- Volunteers
- 30 people
- Sponsor
- ImmuneWorks
Interstitial Lung Disease, Idiopathic Pulmonary Fibrosis
University of Virginia Natural History Study
Data and specimens will be collected longitudinally from patients seen in the UVA Interstitial Lung Disease (ILD) clinic in order to describe the phenotypic expression of various interstitial lung diseases.
- Conditions
- Interstitial Lung Disease, Idiopathic Pulmonary Fibrosis, Sarcoidosis, Connective Tissue Diseases
- Trial name
- NCT04896138
- Testing
- Interstitial Lung Disease
- Where
- United States
- Volunteers
- 2,500 people, healthy volunteers welcome
- Sponsor
- University of Virginia
Idiopathic Pulmonary Fibrosis
Extension Trial of the Long Term Safety of BIBF 1120 in Patients With Idiopathic Pulmonary Fibrosis
The aim of this extension trial is to assess the long-term safety of BIBF 1120 treatment in patients with Idiopathic Pulmonary Fibrosis who have completed one year treatment and the follow up period in the double-blind phase III…
- Trial name
- NCT01619085
- Testing
- Nintedanib
- Where
- 173 sites in United States, Australia and 22 more
- Volunteers
- 752 people
- Sponsor
- Boehringer Ingelheim